Neurocrine Biosciences (NASDAQ:NBIX) Insider Ingrid Delaet Sells 8,433 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $178.72, for a total transaction of $1,507,145.76. Following the completion of the sale, the insider owned 16,225 shares of the company’s stock, valued at $2,899,732. This represents a 34.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, July 7th, Ingrid Delaet sold 3,401 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.57, for a total transaction of $607,316.57.
• On Wednesday, July 8th, Ingrid Delaet sold 2,737 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.54, for a total transaction of $488,663.98.
• On Friday, May 29th, Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31.

Neurocrine Biosciences Price Performance

NBIX stock opened at $180.55 on Friday. The company’s 50-day moving average is $159.92 and its 200-day moving average is $142.66. The stock has a market capitalization of $18.15 billion, a PE ratio of 27.82, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $181.00.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC grew its holdings in Neurocrine Biosciences by 0.5% during the first quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock worth $1,721,000 after buying an additional 68 shares in the last quarter. Huntington National Bank lifted its stake in Neurocrine Biosciences by 12.6% during the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after acquiring an additional 76 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in Neurocrine Biosciences by 3.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after acquiring an additional 78 shares in the last quarter. Motley Fool Asset Management LLC boosted its holdings in Neurocrine Biosciences by 4.8% during the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock worth $240,000 after acquiring an additional 78 shares during the last quarter. Finally, Main Management ETF Advisors LLC boosted its holdings in Neurocrine Biosciences by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock worth $1,111,000 after acquiring an additional 80 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX was upgraded to Zacks Rank #1 (Strong Buy), signaling improved earnings optimism and potentially supporting further upside. Article Title
• Positive Sentiment: News that Neurocrine has started a Phase 2 CAH study in children under 4 may be encouraging for the pipeline, and another article suggested the stock could be undervalued after the new study. Article Title Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30; this is important upcoming catalyst news, but it does not change fundamentals by itself. Article Title
• Neutral Sentiment: A separate note said NBIX looks fair on earnings but pricey versus biotechs, which is more of a valuation check than a clear stock-moving event. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in three transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which limits how bearish the signal is, but insider selling can still temper enthusiasm. Article Title

Analyst Ratings Changes

A number of brokerages have commented on NBIX. Guggenheim reissued a “buy” rating and issued a $175.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. Citigroup upped their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 24th. Needham & Company LLC reissued a “buy” rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a research report on Monday, April 6th. Finally, Morgan Stanley boosted their price target on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $188.10.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.